Raymond L. Benza

23.9k total citations · 8 hit papers
316 papers, 12.2k citations indexed

About

Raymond L. Benza is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Raymond L. Benza has authored 316 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 220 papers in Pulmonary and Respiratory Medicine, 157 papers in Cardiology and Cardiovascular Medicine and 63 papers in Surgery. Recurrent topics in Raymond L. Benza's work include Pulmonary Hypertension Research and Treatments (211 papers), Heart Failure Treatment and Management (59 papers) and Cardiovascular Function and Risk Factors (51 papers). Raymond L. Benza is often cited by papers focused on Pulmonary Hypertension Research and Treatments (211 papers), Heart Failure Treatment and Management (59 papers) and Cardiovascular Function and Risk Factors (51 papers). Raymond L. Benza collaborates with scholars based in United States, Germany and France. Raymond L. Benza's co-authors include Michael D. McGoon, Adaani Frost, Dave P. Miller, David B. Badesch, Robyn J. Barst, Mardi Gomberg‐Maitland, C. Gregory Elliott, Harrison W. Farber, Robert P. Frantz and Aimee J. Foreman and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Raymond L. Benza

295 papers receiving 12.0k citations

Hit Papers

Predicting Survival in Pulmonary Arterial Hypertension 2003 2026 2010 2018 2010 2009 2003 2012 2019 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Predicting Survival in Pulmonary Arterial Hypertension
    2010 1.1k citations Raymond L. Benza, Dave P. Miller et al. Circulation profile →
  2. Pulmonary Arterial Hypertension
    2009 866 citations David B. Badesch, C. Gregory Elliott et al. CHEST Journal profile →
  3. The VIVA Trial
    2003 796 citations Raymond L. Benza et al. Circulation profile →
  4. An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry
    2012 737 citations Raymond L. Benza, Dave P. Miller et al. CHEST Journal profile →
  5. Predicting Survival in Patients With Pulmonary Arterial Hypertension
    2019 390 citations Raymond L. Benza, Mardi Gomberg‐Maitland et al. CHEST Journal profile →
  6. The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension
    2011 389 citations Raymond L. Benza, Mardi Gomberg‐Maitland et al. CHEST Journal profile →
  7. Pulmonary Arterial Hypertension
    2013 378 citations Michael D. McGoon, Raymond L. Benza et al. Journal of the American College of Cardiology profile →
  8. Five-Year Outcomes of Patients Enrolled in the REVEAL Registry
    2015 337 citations Harrison W. Farber, Dave P. Miller et al. CHEST Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raymond L. Benza United States 48 8.8k 7.1k 2.3k 1.8k 1.3k 316 12.2k
Robert P. Frantz United States 49 7.2k 0.8× 6.2k 0.9× 2.9k 1.3× 1.1k 0.6× 712 0.6× 222 10.9k
Iréne Lang Austria 74 11.7k 1.3× 12.3k 1.7× 3.3k 1.5× 2.4k 1.3× 1.7k 1.4× 527 20.4k
Rogério Souza Brazil 39 11.8k 1.3× 6.8k 1.0× 1.6k 0.7× 2.3k 1.2× 1.1k 0.9× 180 13.5k
Ronald J. Oudiz United States 48 10.3k 1.2× 7.7k 1.1× 1.1k 0.5× 1.8k 1.0× 543 0.4× 127 11.7k
Adam Torbicki Poland 50 9.7k 1.1× 10.6k 1.5× 1.7k 0.7× 1.7k 0.9× 619 0.5× 263 15.3k
Harm Jan Bogaard Netherlands 54 9.5k 1.1× 7.0k 1.0× 1.8k 0.8× 699 0.4× 1.8k 1.4× 310 12.5k
Richard N. Channick United States 51 13.0k 1.5× 9.1k 1.3× 1.5k 0.7× 2.9k 1.6× 833 0.7× 222 14.7k
Xavier Jaïs France 62 11.4k 1.3× 6.8k 1.0× 1.7k 0.8× 2.6k 1.4× 659 0.5× 261 12.7k
Ivan M. Robbins United States 42 10.9k 1.2× 7.0k 1.0× 1.4k 0.6× 2.2k 1.2× 892 0.7× 106 12.2k
David Langleben Canada 41 12.3k 1.4× 8.2k 1.2× 1.8k 0.8× 2.2k 1.2× 1.1k 0.9× 163 14.3k

Countries citing papers authored by Raymond L. Benza

Since Specialization
Citations

This map shows the geographic impact of Raymond L. Benza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond L. Benza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond L. Benza more than expected).

Fields of papers citing papers by Raymond L. Benza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond L. Benza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond L. Benza. The network helps show where Raymond L. Benza may publish in the future.

Co-authorship network of co-authors of Raymond L. Benza

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond L. Benza. A scholar is included among the top collaborators of Raymond L. Benza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond L. Benza. Raymond L. Benza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jorde, Ulrich P., Raymond L. Benza, Patrick M. McCarthy, et al.. (2024). Impact of Renal and Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair. Journal of the American College of Cardiology. 84(25). 2446–2456. 2 indexed citations
2.
Benza, Raymond L., Ekkehard Grünig, Peter Sandner, Johannes‐Peter Stasch, & Gérald Simonneau. (2024). The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase. European Respiratory Review. 33(171). 230183–230183. 18 indexed citations
3.
Griffiths, Megan, Catherine E. Simpson, Jun Yang, et al.. (2024). Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models. CHEST Journal. 166(6). 1511–1531. 2 indexed citations
4.
Benza, Raymond L., Gérald Simonneau, Hossein Ardeschir Ghofrani, et al.. (2024). Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study. The Journal of Heart and Lung Transplantation. 43(10). 1756–1760. 1 indexed citations
5.
Chin, Kelly, William R. Auger, Raymond L. Benza, et al.. (2023). Long-term Survival and Quality of Life. 1(2). 100008–100008. 6 indexed citations
6.
MacEwan, Sarah R., Gennaro Di Tosto, Laura J. Rush, et al.. (2023). The Role of Palliative Care in Heart Failure, Part 3: Facilitators and Barriers to Cardiac Palliative Care Clinic Development. Journal of Palliative Medicine. 26(12). 1685–1690.
7.
Benza, Raymond L., David Langleben, Anna R. Hemnes, et al.. (2022). Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Review. 31(166). 220061–220061. 10 indexed citations
8.
Kyvernitakis, Andreas, Mark Doyle, Stephen Bailey, et al.. (2022). Prognostic role of pulmonary hemodynamics before transcatheter aortic valve replacement among patients with severe aortic stenosis. The Journal of Heart and Lung Transplantation. 42(2). 275–282. 3 indexed citations
9.
Benza, Raymond L., Athénaïs Boucly, Harrison W. Farber, et al.. (2021). Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. The Journal of Heart and Lung Transplantation. 41(3). 411–420. 7 indexed citations
10.
Kerr, Kim M., C. Gregory Elliott, Raymond L. Benza, et al.. (2021). The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study. JMIR Research Protocols. 10(5). e25397–e25397. 2 indexed citations
11.
Scott, Jacqueline V., Christine Garnett, Manreet Kanwar, Norman Stockbridge, & Raymond L. Benza. (2020). Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials. American Journal of Respiratory and Critical Care Medicine. 203(6). 726–736. 18 indexed citations
12.
Abraham, Jacob, Rupinder Bharmi, Orvar Jonsson, et al.. (2019). Association of Ambulatory Hemodynamic Monitoring With Clinical Outcomes in a Concurrent Matched Control Analysis.. JAMA Cardiology. 2 indexed citations
13.
Burger, Charles D., et al.. (2017). Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. ClinicoEconomics and Outcomes Research. Volume 9. 731–739. 34 indexed citations
14.
Benza, Raymond L., Verónica Franco, Mark Doyle, et al.. (2016). Abstract 19282: Safety and Utility of the CardioMEMs Device in Pulmonary Arterial Hypertension. Circulation. 134.
15.
Shields, Kelly J., Kostas Verdelis, Michael J. Passineau, et al.. (2016). Three‐Dimensional Micro Computed Tomography Analysis of the Lung Vasculature and Differential Adipose Proteomics in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. Pulmonary Circulation. 6(4). 586–596. 15 indexed citations
16.
Benza, Raymond L., Mardi Gomberg‐Maitland, Teresa DeMarco, et al.. (2015). Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 192(11). 1345–1354. 72 indexed citations
17.
Bourge, Robert C., Victor F. Tapson, Zeenat Safdar, et al.. (2012). Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Cardiovascular Therapeutics. 31(1). 38–44. 29 indexed citations
18.
Benza, Raymond L., Dave P. Miller, Mardi Gomberg‐Maitland, et al.. (2010). Predicting Survival in Pulmonary Arterial Hypertension. Circulation. 122(2). 164–172. 1139 indexed citations breakdown →
19.
Roberts, Kari E., Michael B. Fallon, Michael J. Krowka, et al.. (2009). Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease. American Journal of Respiratory and Critical Care Medicine. 179(9). 835–842. 143 indexed citations
20.
Gomberg‐Maitland, Mardi, Victor F. Tapson, Raymond L. Benza, et al.. (2005). Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine. 172(12). 1586–1589. 174 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert P. Frantz Breakdown of academic impact, for papers by Iréne Lang Breakdown of academic impact, for papers by Rogério Souza Breakdown of academic impact, for papers by Ronald J. Oudiz Breakdown of academic impact, for papers by Adam Torbicki Breakdown of academic impact, for papers by Harm Jan Bogaard Breakdown of academic impact, for papers by Richard N. Channick Breakdown of academic impact, for papers by Xavier Jaïs Breakdown of academic impact, for papers by Ivan M. Robbins Breakdown of academic impact, for papers by David Langleben
Rankless by CCL
2026